On September 13, 2018, STAAR Surgical announced the approval by the FDA of the Visian Toric ICL (TICL) for the correction of myopia with astigmatism. Before the announcement, the Visian ICL (implantable collamer lens) product line in the United States only consisted of lenses that offer correction for patients with myopia (nearsightedness). Visian ICL patients with astigmatism would require an additional LASIK procedure to correct that refractive error. Price Vision Group has been performing procedures with the standard Visian ICL since 2004.
This announcement is incredible news for our patients with high myopia and astigmatism who were not candidates for LASIK or PRK. “FDA’s approval of STAAR’s Visian Toric ICL in the U.S. provides an exciting treatment option for myopic patients with astigmatism in search of visual freedom. We are thrilled to be able to offer this lens in the United States and look forward to officially making the Visian Toric ICL available to U.S. surgeons for their patients on November 1st, 2018,” said Caren Mason, President & CEO.
Offering our patients the best vision correction options is our top priority and we will update our patients on the availability of the Visian Toric ICL when we receive them.
To learn more about the Visian ICL and to see if it’s right for you, please click here.